What is this medicine used for?
FDA-approved uses
- Attention-deficit/hyperactivity disorder (ADHD) — Adults and children aged 6 years and older. Part of a broader treatment program that may include psychological, educational and social measures. It is not approved for depression.atomoxetine hydrochloride oral capsules.
Read more: ADHD.
What should I expect?
Some improvement may begin in the first week, but fuller benefit can take up to a month. Follow attention, impulsivity, and daily functioning over time rather than expecting the same day-by-day experience as a stimulant.
Agree on a follow-up plan when treatment starts. Contact the prescriber if symptoms worsen, side effects disrupt daily life, or there is no useful improvement by the planned review; do not change the dose yourself.
How do I take it safely?
Swallow capsules whole with or without food; do not open them. The prescribed schedule may be once in the morning or divided between morning and later in the day. If capsule contents contact the eyes, rinse with water and obtain medical advice.
Keep pulse and blood-pressure checks, including after dose changes; children also need growth and behavior monitoring. Liver problems, known slow metabolism, or interacting medicines can change how treatment is introduced.
MAOI use or failure to allow the required 14-day interval when switching in either direction. Narrow-angle glaucoma; pheochromocytoma or a history of that tumor. Severe cardiovascular disorders likely to worsen with clinically important increases in pulse or blood pressure, or allergy to ingredients.
Review bipolar episodes, urinary retention, and any new hallucinationsHallucinationsA hallucination is a sensory experience without a corresponding external source—for example, hearing a voice when nobody is speaking. It can involve hearing, sight, touch, smell or taste and may feel very real.A hallucination is an experience; a delusion is a belief. Hallucinations can have different causes, so an assessment is needed to understand them. or unusual mood elevation with the prescriber.
Fluoxetine, paroxetine and other strong CYP2D6 inhibitors increase atomoxetine exposure and change the permitted titration interval. MAO inhibitors must not be combined. Blood-pressure medicines, medicines that raise blood pressure and albuterol or other beta-2 agonists require review and may need closer pulse or blood-pressure monitoring. A pharmacist should check the full medicine list.
Available pregnancy studies are insufficient to establish the medication’s risk; discuss treatment benefits and alternatives with the clinician. The current reference label states that human milk and infant-effect data are lacking, so breastfeeding requires a benefit–risk discussion rather than an assumption of safety.
Safety and effectiveness below age 6 are not established. Children need growth and behavior monitoring. Geriatric safety and effectiveness have not been established, and older adults may have additional cardiovascular or medication-interaction concerns.
The current label says to take a missed dose as soon as possible without exceeding the prescribed total daily amount in any 24-hour period. Ask the pharmacist when timing is uncertain. Atomoxetine does not require a taper according to its label, but planned stopping should still be discussed so ADHD symptoms and any adverse effects can be reviewed.
What side effects should I know about?
- Nausea, abdominal discomfort, lower appetite, tiredness or sleepiness.
- Dry mouth, constipation, dizziness and sexual or urinary side effects, particularly in adults.
Tell your prescriber about effects that are persistent, troublesome, or interfere with daily life.
Looking for more detailed information?
The official medicine information lists more side effects, safety advice and product instructions.
- View FDA Prescribing Information (PDF) (opens in a new tab)Strattera reference labeling for atomoxetine capsules
Which warning signs need help?
- New suicidal thoughts or marked behavioral changes need prompt help; immediate danger requires emergency care.
- Yellow skin or eyes, dark urine, itching or unexplained upper abdominal pain may signal liver injury.
- Chest pain, fainting, severe allergic swelling or a prolonged painful erection need urgent assessment.
What else should I know to stay safe?
- Do not use with an MAOI without the required 14-day interval in either direction, after a product allergy, with narrow-angle glaucoma, or with a current or past pheochromocytoma tumor. Severe cardiovascular conditions that could worsen with higher pulse or blood pressure also rule out use under the label.
- Measure pulse and blood pressure before treatment, after increases, and periodically; children need growth and behavior monitoring. Review bipolar episodes, liver impairment, urinary retention, and interacting medicines such as fluoxetine, paroxetine, blood-pressure drugs, and albuterol. Slow metabolism can change the treatment plan. Do not open capsules because their contents can irritate the eyes.
- Discuss pregnancy, breastfeeding, and planned stopping with the prescriber. The label does not require a taper, but symptom control and adverse effects still need review. Evidence is insufficient below age 6 and in older adults, and human lactation information is limited.
Urgent help and crisis support · Emergency & Crisis Resources (US)
What can help day to day?
- Not being a stimulant does not mean that pulse and blood-pressure checks are unnecessary. Atomoxetine can affect both.
- Do not open a capsule to make it easier to take. Its contents can irritate the eyes; ask the pharmacist about swallowing difficulties.
How does it work?
Atomoxetine reduces the return of norepinephrine, a chemical messenger, into nerve cells after it has been released. This allows more of the messenger to remain available between cells. Researchers do not yet fully understand how this action leads to improvement in attention-deficit/hyperactivity disorder (ADHD) symptoms.
How was this medicine developed?
The FDA approved Strattera in 2002, adding a nonstimulant approach to ADHD treatment. Its safety information emphasizes mood and behavior in younger patients, liver injury, and heart and blood-pressure effects. The current reference label also addresses differences in how people break the medicine down.
How do I say the name?
Atomoxetine: AT-oh-mox-eh-teen. Capital letters show the stressed syllable.
Sources and References
Sources support the U.S. products described here. Product instructions can differ; use the information supplied with your own medicine.
- Atomoxetine / Strattera: current reference-product labeling
- Atomoxetine: patient information
- Strattera: FDA approval history and discontinued product record
- Atomoxetine / Strattera: FDA prescribing information, June 2026
- Atomoxetine: Package Insert / Prescribing Information / MOA
- DailyMed - ATOMOXETINE capsule
- FDA determination: Strattera was not withdrawn for safety or effectiveness
- Generic atomoxetine capsules: product labeling
- ISMP List of Confused Drug Names
- Schizophrenia
- NIMH: Understanding psychosis
Giving medicine safely to children: family guide (PDF, 3 pages)

